SCHEMBL6967355

SCHEMBL6967355

Clc1cccc(OCC2CCc3[nH]cnc3C2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 4/20 0.49
TAAR1 Q96RJ0 1/20 0.44
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCNA1 P78396 1/20 0.37
CCNB3 Q8WWL7 1/20 0.37
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HRH3 Q9Y5N1 2/20 0.36
GRM2 Q14416 1/20 0.35
HTR6 P50406 1/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6960436 0.85 LMNA (0.40) ADRA1ALMNA
SCHEMBL6963392 0.85 CHRNB2 (0.41) ADRA1A
SCHEMBL6962031 0.84 SLC6A2 (0.42) ADRA1ASLC6A4SLC6A2SLC6A3
SCHEMBL6960596 0.83 SGPL1 (0.43) ADRA1A
SCHEMBL6962600 0.83 KMT2A (0.44) ADRA1ALMNAHRH3GRM2SLC6A4
SCHEMBL6957018 0.82 SLC6A2 (0.53) ADRA1AMAPK1SLC6A4SLC6A2SLC6A3
SCHEMBL6954587 0.79 ADRA1A (0.48) ADRA1AGRM2SLC6A4SLC6A2
SCHEMBL6956969 0.79 CYP2D6 (0.43) SMN1; SMN2HRH3
SCHEMBL6960181 0.77 MAOB (0.43) ADRA1ALMNAMAPK1SMN1; SMN2HTR6
SCHEMBL6964044 0.77 ADRA1A (0.37) ADRA1ASLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 US disclosed
EP-1268483-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-20010049385-A1 Imidazo heterocyclic compounds HIGH POINT PHARMACEUTICALS, LLC 2001-12-06 US disclosed
WO-2001068651-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049385-A1 Imidazo heterocyclic compounds HRH4, HRH3, HRH2 ADRA1A 212/4885TAAR1 115/4885CCNB2 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.